Phaseline

Targets › FKS1

FKS1: drug programs, companies and trials

3 programs from 3 companies in 7 trials: 3 Phase 1, 2 Phase 3, 2 Phase 2; Infectious disease, Respiratory, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: the race on FKS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Basilea Pharmaceuticafosmanogepix
GPI-anchored wall transfer protein 1 inhibitor
IPCS1, HMG1, FKS1Phase 3Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on DialysisMar 2027
Mundipharma ResearchRezafungin Acetate
1,3-beta-D-glucan synthase inhibitor
FKS1Phase 2Pneumocystis Pneumonia; Chronic Pulmonary AspergillosisNov 2026
University Hospital, ToursCaspofungin
1,3-beta-glucan synthase inhibitor
FKS1Phase 1Pneumocystis PneumoniaDec 2026

Conditions

Pneumocystis Pneumonia (2) Candidemia (1) Invasive Mold Infections (1) Healthy Adult Participants (1) End Stage Renal Disease on Dialysis (1) Chronic Pulmonary Aspergillosis (1)

Modalities

small molecule (3)

Companies

Basilea Pharmaceutica (1) University Hospital, Tours (1) Mundipharma Research (1)

Related targets

IPCS1 (1) HMG1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.